Agoracom Blog Home

Posts Tagged ‘CBD’

« Older Entries
Newer Entries »

#Cannabis-laced drinks could be a US$600m market in US by 2022 $NBUD.ca $TAP $WEED.ca $KO

Posted by AGORACOM-JC at 10:18 AM on Friday, September 28th, 2018
  • Beverages with CBD (cannabidiol) or THC (tetrahydrocannabinol) ingredients could grow to capture about 20 per cent of the US market for edible pot products by 2022, up from 6 per cent of edibles sold now
  • Canaccord sees the demand for beverages featuring CBD, the non-psychoactive compound in marijuana, reaching US$260 million by 2022, up from the “negligible revenue” the limited number of drinks contributes now, while THC-based drinks could reach US$340 million, up from US$106 million expected this year

Sep 27, 2018 (Euclid Infotech Ltd via COMTEX) — Drinks infused with marijuana-derived compounds could swell to become a US$600 million market in the US within the next four years, outpacing the growth of other categories of retail cannabis products, according to analysts at Canaccord Genuity.

Beverages with CBD (cannabidiol) or THC (tetrahydrocannabinol) ingredients could grow to capture about 20 per cent of the US market for edible pot products by 2022, up from 6 per cent of edibles sold now, Canaccord’s Bobby Burleson wrote in a note. It’s an opportunity mainstream beer and soda makers are eager to take part in – Corona-parent Constellation Brands Inc became the largest stakeholder in Canadian pot cultivator Canopy Growth Corp earlier this year, while Molson Coors Canada formed a joint venture with Hexo Corp. Also, Coca-Cola Co said it’s exploring the idea.

“Interest has spiked from the beer industry on mounting evidence of a substitution relationship between cannabis and alcohol, while large soda companies increasingly view CBD as a natural fit within their strategically important wellness offerings,” Mr Burleson wrote.

Canaccord sees the demand for beverages featuring CBD, the non-psychoactive compound in marijuana, reaching US$260 million by 2022, up from the “negligible revenue” the limited number of drinks contributes now, while THC-based drinks could reach US$340 million, up from US$106 million expected this year.

Source: https://www.marketwatch.com/press-release/united-states-cannabis-laced-drinks-could-be-a-us600m-market-in-us-by-2022-2018-09-27

Tags: , , , , ,
Posted in All Recent Posts, Featured, North Bud Farms Inc | Comments Off on #Cannabis-laced drinks could be a US$600m market in US by 2022 $NBUD.ca $TAP $WEED.ca $KO

North Bud Farms $NBUD.ca Announces Licensing of #Cannabinoid Infusion Technology for Food and Beverage Platform $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 4:13 PM on Thursday, September 27th, 2018

Northbud large

  • Announced the licensing of infusion technology for its food and beverage platform with Made By Science Inc., a wholly owned subsidiary of Form Factory Inc.
  • Company signed a supply and licensing agreement with Made By Science Inc. , an Oregon, California multi state co-packaging and infused product manufacturer.
  • MBS owns a variety of IP protected infusion, encapsulation, taste masking and manufacturing processes

TORONTO, Sept. 27, 2018 – North Bud Farms Inc. (CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to announce the licensing of infusion technology for its food and beverage platform with Made By Science Inc., a wholly owned subsidiary of Form Factory Inc.

The Company signed a supply and licensing agreement with Made By Science Inc. (“MBS”), an Oregon, California multi state co-packaging and infused product manufacturer. MBS owns a variety of IP protected infusion, encapsulation, taste masking and manufacturing processes.

This Agreement provides that NORTHBUD will purchase from MBS raw, non-infused protein-based encapsulation powder (MX-17) to be used for infusion and formulation purposes in the Canadian market. NORTHBUD and MBS have established a per gram cost as well as a royalty agreement where NORTHBUD will pay a floating royalty on business to business sales and a consumer direct sale.

The companies intend to negotiate a master licensing agreement (“the Agreement”) to include the licensing and use of multiple proprietary food infusion technologies for which MBS will grant a master license for NORTHBUD to the use of the patented technology.

“Over the past 8 months our team has researched many technology solutions pertaining to encapsulation and infusion of cannabinoids into foods and beverages,” said Ryan Brown, Founder and CEO of North Bud Farms Inc. “This agreement secures us access to a premier technology partner allowing us to leverage a proven technology and tested processes from an advanced consumer market. We believe this will accelerate NORTHBUD’s goal of developing a food grade cannabinoid infused taste neutral ingredient as a first step towards creating products that will follow in compliance with the upcoming regulations regarding infused consumables. Over the coming months we look forward to working with both Food and Cannabis industry participants as we establish our development platform in preparation for the legalization of edibles and consumables which is anticipated in October 2019.”

“Made By Science has been relentlessly innovating the science driving the infused edibles industry to provide brands and consumers with safe, efficient and accurate products. As our team continues to position as a best in class manufacturer in the U.S., we have had our sights set on Canada as both critical to our long-term expansion and essential for our ability to export to international markets. NORTHBUD was an early believer in our technology and our team and we are excited to support their efforts with innovation and scale,” said Joshua Held, President of Form Factory Inc.

In accordance with the corporate stock option plan, North Bud Farms has issued 85,000 options at a strike price of $0.60 to advisors and consultants assisting with this project. These options will vest over a 24-month period.

About Made By Science Inc.
Made By Science Inc. is a wholly owned subsidiary of Form Factory Inc., a multi state manufacturer of cannabis infused food and beverage products.

For more information visit: www.madebyscience.co

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).   North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Tags: , , , ,
Posted in All Recent Posts, North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Announces Licensing of #Cannabinoid Infusion Technology for Food and Beverage Platform $ACB $WEED.ca $HIP.ca

INTERVIEW: North Bud Farms $NBUD.ca Discusses Licensing of #Cannabinoid Infusion Technology for Food and Beverage Platform

Posted by AGORACOM-JC at 4:02 PM on Thursday, September 27th, 2018

Tags: , , , ,
Posted in AGORACOM Via Satellite, Featured, North Bud Farms Inc | Comments Off on INTERVIEW: North Bud Farms $NBUD.ca Discusses Licensing of #Cannabinoid Infusion Technology for Food and Beverage Platform

North Bud $NBUD.ca Farms to Begin Trading on the Canadian Securities Exchange

Posted by AGORACOM-JC at 8:17 AM on Wednesday, September 19th, 2018

Northbud large

  • will commence trading on the Canadian Securities Exchange at the opening of the market on Thursday, September 20, 2018 under the stock symbol NBUD

TORONTO, Sept. 19, 2018 — North Bud Farms Inc. (“NORTHBUD” or the “Company“) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (“CSE”) at the opening of the market on Thursday, September 20, 2018 under the stock symbol “NBUD”.

“We are proud to achieve this milestone in advance of the historic legalization of Cannabis in Canada on October 17, 2018 and less than 10 months since the Company’s inception which is a testament to the dedication and execution of our experienced management team,” said Ryan Brown, Founder and CEO of North Bud Farms.

Concurrently with the CSE listing, the Company also announces that the board of directors has authorized the grant of 5,100,000 incentive stock options to certain of its directors, officers, employees and consultants. Each such option entitles the holder to acquire one common share for a period of 5 years at an exercise price of $0.25 per common share.

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).   North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Tags: , , , , ,
Posted in Featured, North Bud Farms Inc | Comments Off on North Bud $NBUD.ca Farms to Begin Trading on the Canadian Securities Exchange

Tetra Bio-Pharma $TBP.ca Accelerates its European Drug Registration Activities $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:24 AM on Tuesday, September 11th, 2018

Logo tetrabiopharma rgb web

  • Announced today that it is accelerating the submission of a pre-marketing application for the registration of its cannabis drugs PPP001 and PPP005 under Directive 2001/83/EC of the European Parliament and of the Council. 
  • This directive provides Tetra Bio-Pharma with the legal and regulatory framework needed to submit its pre-marketing application for its cannabis drugs

PPP001 and PPP005 Eligible for Marketing Approval

ORLEANS, Ontario, Sept. 11, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it is accelerating the submission of a pre-marketing application for the registration of its cannabis drugs PPP001 and PPP005 under Directive 2001/83/EC of the European Parliament and of the Council.

This directive provides Tetra Bio-Pharma with the legal and regulatory framework needed to submit its pre-marketing application for its cannabis drugs.  According to Dr. Guy Chamberland, Interim CEO and CSO, “the corporation has performed its own clinical trials and has sufficient quality and clinical trial data to initiate the application for the registration of PPP001 and PPP005 under the Directive 2001/83/EC.  Tetra intends to pursue a Full Market Authorisation since it has a dossier supporting the medicinal product’s quality, safety, and efficacy.”

All of Tetra’s clinical trials were performed with the same quality of evidence required by the National Competent authorities approving medicines/drugs.  Tetra has completed several well-designed safety, pharmacodynamic and pharmacokinetic studies in healthy volunteers and also has two ongoing, well-designed clinical trials in patients.  These trials are all double-blind, randomized and placebo controlled.

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the approval of PPP001 and/or PPP005 by the European Medicines Agency, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

Tags: , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Accelerates its European Drug Registration Activities $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma $TBP.ca Secures CBD Supply Agreement for Genacol Partnership $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:17 AM on Wednesday, September 5th, 2018

Logo tetrabiopharma rgb web

  • Announced that it has secured a CBD supply agreement with True North Cannabis in Alberta, Canada. 
  • Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation which will be commercialized under the previously announced partnership with Genacol

ORLEANS, Ontario, Sept. 05, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that it has secured a CBD supply agreement with True North Cannabis in Alberta, Canada.  Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation which will be commercialized under the previously announced partnership with Genacol.

Tetra Bio-Pharma will use its formulation and regulatory expertise and clinical trial data from its topical cannabinoid and encapsulated cannabis oil (PPP005) trials to create these innovative products for Genacol.  Tetra Bio-Pharma will work with the appropriate regulatory agencies to gain marketing authority within Genacol’s international sales network where their brand products are available in more than 40 countries, including Latin America, Europe, Asia, the Middle East, Africa and the United States. In addition, the Genacol trademark is registered in 81 countries worldwide. According to industry statistics the market for topical pain relief products exceeds $2.5 billion. The products are expected to be launched in 2019.

“We are very pleased to secure a competitive supply agreement with True North Cannabis as Tetra is committed on bringing innovative cannabinoid products to market,” says Dr. Guy Chamberland, interim CEO and Chief Scientific Officer of Tetra Bio-Pharma.  “True North Cannabis has built a state-of-the-art facility in Alberta which will provide the highest quality CBD for Tetra, at a competitive price, to develop innovative products in partnership with Genacol.  Price to consumers is a critical aspect for the viability of a commercial product in the self-care health market.  At Tetra Bio-Pharma we are focused on becoming a global leader in the development of cannabinoid derived prescription and natural health products.”

“True North Cannabis is pleased to enter into a commercial relationship to supply hemp-based CBD to Tetra Bio-Pharma,” Shayne Hamilton, Chief Executive Officer of True North Cannabis commented.  “Our business leverages the size and scale of the industrial hemp crop in Canada to provide a competitively priced, reliable source of CBD.  Tetra Bio-Pharma’s vast experience in pharmaceutical product development, along with Genacol’s robust distribution footprint, presents True North Cannabis a unique opportunity to market our product.”

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

About True North Cannabis
True North Cannabis (TNC) is a Canadian hemp harvest service provider with a core focus on facilitating the supply of bulk, extract-ready, hemp-based CBD.

With a grower-focused service model, TNC supports industrial hemp growers across Canada to effectively commercialize the cannabinoid content from their harvest.  By providing access to state of the art infrastructure and hemp chaff expertise, TNC manages the unique challenges in bridging broad acre agriculture and the Cannabis industry.

For more information visit: www.truenorthcannabis.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, and the success of its natural health products development and commercialization strategies,  and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
energi PR
Carol Levine
[email protected]
514-288-8500 ext. 225
416-425-9143 ext. 225

Tags: , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Secures CBD Supply Agreement for Genacol Partnership $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America $MCOA Provides Update on Its Investment in MoneyTrac Technology $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:22 AM on Wednesday, August 29th, 2018

15233 mcoa

  • Announced that it has received 150,000,000 shares of common stock of Global Payout Inc. as part its reverse merger with MoneyTrac Technology
  • Based on the market price of GOHE’s stock on the date of the share issuance, MCOA has a contingent unrealized gain of approximately 700% on its $250,000 investment, subject to future price fluctuations in the market for GOHE’s stock.

Escondido, California–(August 29, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that it has received 150,000,000 shares of common stock of Global Payout Inc. as part its reverse merger with MoneyTrac Technology. Based on the market price of GOHE’s stock on the date of the share issuance, MCOA has a contingent unrealized gain of approximately 700% on its $250,000 investment, subject to future price fluctuations in the market for GOHE’s stock.

On March 13, 2017, MCOA entered into a stock purchase agreement to acquire 15,000,000 common shares of MoneyTrac Technology, Inc., for a total purchase price of $250,000. As part of MoneyTrac’s merger with GOHE, GOHE issued shares from treasury to MCOA on August 24, 2018. On the date of the share issuance, the closing price of GOHE’s stock was $.0116 a share, valuing the 150M shares position at approximately $1,740,000.

Regarding the share issuance, Don Steinberg, President and CEO stated, “We are pleased to announce that we have received a substantial amount of stock in GOHE. Since we are receiving stock in a publicly traded company, we have the opportunity to realize a gain from our investment in MoneyTrac to help provide the Company with capital to help accomplish our aggressive growth goals and business plan in 2018.”

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Global Payout, Inc.

Since the Company’s inception in 2009, Global Payout, Inc. has been a leading provider of comprehensive and customized prepaid payment solutions for domestic and international organizations distributing money worldwide. In 2014, Global introduced its first online payment platform called the Consolidated Payment Gateway (CPG), which allowed its enterprise clients to transfer money to international bank accounts, mobile accounts, and prepaid card accounts. The development of the CPG became the foundation for the introduction of its new, state of the art FINTECH payment system in 2017, for both online and mobile applications to allow account holders to maximize an expanded suite of financial services and minimize operational costs. Global will continue to offer their FINTECH payment system to many vertical markets for support of foreign currency exchange and digital currency, including ongoing support of the banking industry and international governments.

About MoneyTrac Technology

MoneyTrac Technology, Inc. (MTRAC) is a “New Age Technology Holding Company” offering a full-service solution for alternative banking and electronic financial marketplace with technology offerings including Payment Platform, Blockchain, Crypto-Commodity Exchange, Compliance, POS, E-Wallet, Mobile Application and Digital Payment Solutions for businesses and companies in various “high-costs of banking” industries. MTRAC offers additional suites of services ranging from business development, sales and marketing, to digital and print advertisement. We are One Network disrupting the status quo. It is MTRAC’S creative vision to create a “The New Age of Currency™” by bringing innovative technology solutions to various industries and providing the “Key to Cashless™.”

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , ,
Posted in Marijuana Company of America | Comments Off on Marijuana Company of America $MCOA Provides Update on Its Investment in MoneyTrac Technology $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Namaste $N.ca $NXTTF announces supply agreement with #Bonify and acquisition of over 14,000 registered users with #NamasteMD $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:14 AM on Wednesday, August 22nd, 2018

  • Signed a wholesale supply agreement with Manitoba-based ACMPR Licensed producer, Bonify Inc.
  • Under the terms of the Supply Agreement, Namaste will purchase bulk cannabis products through the Company’s wholly-owned subsidiary, Cannmart Inc

VANCOUVER, Aug. 22, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company has signed a wholesale supply agreement (the “Supply Agreement”) with Manitoba-based ACMPR Licensed producer, Bonify Inc. (“Bonify”). Under the terms of the Supply Agreement, Namaste will purchase bulk cannabis products through the Company’s wholly-owned subsidiary, Cannmart Inc. (“Cannmart”).  Bonify operates a large-scale cultivation facility and will expand capacity to over 350,000 square-foot that will accommodate Namaste’s growth trajectory. Namaste will work with Bonify to develop private-label strains of cannabis for the medical and recreational markets as well as in offering the full selection of Bonify products.

Further to the Company’s August 13th news release, Cannmart completed its Health Canada Pre-Sales inspection on July 31st, 2018 and the receipt of its “sales-only” license will represent a major milestone for the Company. With Cannmart’s “sales-only” license imminent, and in order to accommodate the acceleration of NamasteMD’s (NamasteMD.com) database and with the launch of Canadian recreational cannabis sales pending, the Supply Agreement with Bonify will guarantee adequate supply to support Namaste’s demand.

Namaste is also pleased to announce that it has registered over 14,000 users in its online patient portal and mobile app, NamasteMD representing a 130% increase in registered users in approximately 2 months. With the latest launch of the NamasetMD app, the Company has streamlined the on-boarding process, improved conversion rates and has opened the app’s scheduling to accommodate appointments within 15 minutes from sign-up. The accelerated growth in patient acquisition which has taken place over the past two and a half months is extremely encouraging. Namaste anticipates seeing further acceleration once Cannmart’s sales license is received and cannabis sales are integrated within the platform.

The Company is also pleased with initial results from the launch of its patient feedback app, Uppy Strain Journal (“Uppy”), with over 11,000 downloads from its launch one month ago. Data collection through Uppy will drive machine learning algorithms that will be used in tandem with cannabis strain data to provide better strain recommendations for medical patients. By adding value for medical patients in an online environment, Namaste will achieve lower cost per patient acquisition, higher conversion rates, increased revenue and provide a better user experience.

Namaste’s e-commerce platform and technology will continue to drive innovation that will have a major impact on the way in which patients can access medical cannabis online. Namaste’s goal is to create the most comprehensive user experience possible by personalizing product and strain recommendations through integration of its AI technology, providing convenient access to healthcare practitioners through its patient portal, NamasteMD, and to drive cannabis sales through Cannmart.

Management Commentary

Dalbir Bains, President and CEO of Bonify comments: “We are thrilled to be partnering with the leading cannabis technology company in Canada.  We have witnessed firsthand the impact Namaste MD is having on patients by providing the most convenient and accessible health care experience regardless of whether you live in an urban or rural market thanks to its telehealth capabilities.  The addition of Cannmart, which is coming shortly, will truly complete the patient experience from symptom to diagnosis, from a health care practioner, to receiving a product that will improve the quality of the patient’s life.  This aligns with Bonify’s mission of improving the lives of our patients”.

Sean Dollinger, President and CEO of Namaste comments: “We’re very excited to be working with Bonify and their team. I was personally on-site at their facility in Winnipeg and was very impressed with their operations and the quality of their products. Bonify will be a strong supply partner for Namaste as they understand our vision and have significant capacity to support our growing patient network. We’re in a key position now where many of our efforts are coming together with our anticipated sales license at Cannmart. We’re looking forward to expanding on our relationship with Bonify in the future and are very excited to be seeing all of these pieces now coming together. The Agreement with Bonify will ensure supply availability for Namaste during a period going in to recreational legalization where many producers anticipate a supply shortage.

I’m very happy to see incredible results in our progress with NamasteMD and Uppy. These platforms will provide Namaste with long term value in domestic and international markets. We will continue to focus on developing our e-commerce platform to encompass everything cannabis. We’re very excited for the future, looking forward to receiving our sales license soon and in rolling-out Cannmart’s platform. We believe that Namaste will emerge as the dominant leader in cannabis e-commerce sales globally and have already established the infrastructure to achieve this goal.”

About Bonify Inc.

Bonify is a Canadian-owned Licensed Producer and leading provider of medical cannabis. By maximizing research findings and strictly adhering to best-in-class practices, quality standards and procedures, Bonify produces medical cannabis products to help individuals get the most out of life each and every day. With over 1,000,000 square feet of potential productive capacity at its present site in Winnipeg, Manitoba, Canada, when at full scale, Bonify will be capable of growing over 100,000 kg of cannabis annually. For more information, visit www.bonify.com.

About Namaste Technologies Inc.

Namaste Technologies is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste’s product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the company will soon be selling medical cannabis in the Canadian market, subject to approval by Health Canada.

Namaste has developed and acquired innovative technology platforms including NamasteMD.com, Canada’s first Health Canada compliant telemedicine application, and in May 2018 the Company acquired a leading e-commerce AI and Machine Learning Company, Findify AB. Findify uses artificial intelligence algorithms to optimize and personalize a consumer’s on-site buying experience. Namaste is focused on leveraging its cutting-edge technology to enhance the user experience throughout its platforms. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (604) 355 6100

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press release.

View original content with multimedia:http://www.prnewswire.com/news-releases/namaste-announces-supply-agreement-with-bonify-and-acquisition-of-over-14-000-registered-users-with-namastemd-300700862.html

Tags: , , , , , ,
Posted in All Recent Posts, Featured, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF announces supply agreement with #Bonify and acquisition of over 14,000 registered users with #NamasteMD $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Genacol Canada Corporation and Tetra Bio-Pharma $TBP.ca Team Up to bring Innovative Cannabinoid Treatments to Self-Care Market in Canada $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:28 AM on Tuesday, August 14th, 2018

Logo tetrabiopharma rgb web

  • Announced that they have concluded a Development and Commercialization agreement with Genacol Canada Corporation.
  • Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation.

ORLEANS, Ontario, Aug. 14, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that they have concluded a Development and Commercialization agreement with Genacol Canada Corporation.  Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation.  Genacol will be responsible for the promotion and sales of these products throughout their network in Canada.  According to industry statistics the market for topical pain relief products exceeded $2.5 billion. The companies plan to launch the products in 2019.

Genacol Topical Gel Cannabidiol Tetra Bio-Pharma

Cannabidiol capsules help relief pain

Tetra Bio-Pharma will use its formulation and regulatory expertise and clinical trial data from its topical cannabinoid and encapsulated cannabis oil (PPP005) trials to create innovative products for Genacol.  Tetra Bio-Pharma will work with regulatory to bring these products to markets within Genacol’s sales network.  “We are thrilled to partner with Genacol, a market leader in Canada with a sales network in over 40 countries, these products will command a great deal of exposure,” says Dr. Guy Chamberland, interim CEO and Chief Scientific Officer of Tetra Bio-Pharma. “Tetra is in the business of developing cannabinoid derived prescription and natural health products and this agreement will enable Tetra Bio-Pharma to expand the number of offerings to our patients.”

“We are extremely excited about the potential of this partnership we have created with Tetra Bio-Pharma, a world leader in developing cannabinoid derived prescription and natural health products,” stated Martin Vidal, President & Chief Executive Office for Genacol Corporation.  “Our research team at Genacol are great believers in the therapeutic properties of cannabinoids. These products that Tetra Bio-Pharma is developing and Genacol will promote and commercialize are expected to play an important role in the pain and inflammation market in Canada. We estimate that these products will generate several millions of dollars in sales for Genacol in Canada.”

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

About Genacol Corporation
Genacol Corporation Canada is a leader in the development and marketing of natural health products primarily related to the treatment of joint pain and the maintenance of joint health. Its mission is to improve the quality of life of its customers by offering them a range of innovative natural products. Building on its success in Canada, Genacol has also developed in recent years an international presence with Genacol brand products available in more than 40 countries, including Latin America, Europe, Asia, the Middle East, Africa and the United States. In addition, the Genacol trademark is registered in 81 countries worldwide. The success of Genacol is based on its collagen manufactured using a proprietary process called “AminoLock® Sequential Technology”, which is an ingredient in many of Genacol’s products.

 

For more information visit: www.genacol.ca/en/about-us/

 

Source: Tetra Bio-Pharma

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact:
ACJ Communication
Daniel Granger
[email protected]
514-840-7990
514-232-1556

Photos accompanying this announcement are available at

 

http://www.globenewswire.com/NewsRoom/AttachmentNg/b867bc64-b347-4043-80ff-c7d022ab7eff

 

http://www.globenewswire.com/NewsRoom/AttachmentNg/3464aadf-745d-4d04-b230-b71f0c82188a

Tags: , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Genacol Canada Corporation and Tetra Bio-Pharma $TBP.ca Team Up to bring Innovative Cannabinoid Treatments to Self-Care Market in Canada $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma $TBP.ca Announces Initiation of Coverage by Paradigm Capital $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 4:06 PM on Monday, August 13th, 2018

Logo tetrabiopharma rgb web

  • Announced that Paradigm Capital, an independent investment banking and advisory group, based in Toronto, has initiated research coverage of Tetra Bio-Pharma.
  • Coverage by Paradigm represents another step forward as Tetra Bio-Pharma increases its visibility in the capital markets.

ORLEANS, Ontario, Aug. 13, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced that Paradigm Capital, an independent investment banking and advisory group, based in Toronto, has initiated research coverage of Tetra Bio-Pharma.

Today’s initiation of coverage by Paradigm represents another step forward as Tetra Bio-Pharma increases its visibility in the capital markets.

To access the report, visit Tetra Bio-Pharma’s Investors section of its website under Analysts: http://tetrabiopharma.com/investors/analysts/default.aspx

About Paradigm Capital Inc.

Paradigm Capital Inc. (PCI) is a research-driven, independent, institutional equity investment dealer focused on sectors and companies that have attractive long-term secular growth prospects. PCI’s research is available on our website at www.paradigmcap.com

About Tetra Bio-Pharma Inc.

Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Tags: , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Announces Initiation of Coverage by Paradigm Capital $AERO $CBDS $CGRW $APH.ca $GBLX

« Older Entries
Newer Entries »